2026 Emerging Topic Conference(On-Demand): Unified Frontiers in Liver Disease — Treating Steatosis, Cholestasis, & Beyond
Availability
On-Demand
10 Courses
Expires on Apr 07, 2027
Cost
Member: $200.00
Non-Member: $400.00
Patient: $0.00
Associate: $125.00
Student: $0.00
Early Career: $125.00
Industry Rep: $400.00
Credit Offered
32.25 AMA PRA Category 1 Credits
13.5 Participation Credits
  • Description
  • Learning Objectives
  • Faculty and Disclosures:
  • Accreditation Information
  • Privacy Policy
The 2026 Emerging Topic Conference: Unified Frontiers in Liver Disease—Treating Steatosis, Cholestasis, and Beyond provides a comprehensive, multidisciplinary exploration of evolving approaches to liver disease management. This recorded program examines emerging therapeutic strategies for cholestatic diseases, alongside the metabolic, environmental, and behavioral drivers of steatotic liver disease (SLD). Participants gain insight into advancing concepts such as MetALD, the effectiveness and limitations of current MASLD therapies, and innovative, technology-enabled care models. The course also highlights how new scientific discoveries are shaping clinical practice and informing public health policy, with a focus on translating research into real-world impact.
Upon completion of this activity, participants should be able to:

  • Explore the metabolic, genetic, and environmental factors driving liver pathogenesis
  • Assess evolving concepts in MASLD, MetALD, and their clinical implications
  • Redesign clinical approaches for diagnosis and treatment using biomarker driven strategies
  • Evaluate the efficacy and limitations of current and experimental treatment pathways
  • Engage with future-forward topics, including digital pathology and translational research
This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias.

All relevant conflicts pertaining to this activity have been mitigated. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PLANNERS:

Alina M. Allen, MD
Scientific Consultant/Advisor: Novo Nordisk, Madrigal, Boehringer Ingelheim, 89Bio, GlaxoSmithKline
Grants/Research Support: Target Pharma, Escopics, Oncoustics, Novo Nordisk, Madrigal, Boehringer Ingelheim, Siemens

Cara Mack, MD, FAASLD
Scientific Consultant/Advisor: Albireo, Ipsen

Craig Lammert, MD, MS
Scientific Consultant/Advisor: Kezar Life Sciences, Eli Lilly, RegCell

Cynthia Levy, MD, FAASLD
Scientific Consultant/Advisor: Chemomab, Pliant, Kowa, Mirum, GSK, CymaBay, Ipsen, Intercept, Target RWE, Gilead
Grant/Research Support: Intercept, Ipsen, CymaBay, Calliditas, Kowa, Zydus, Pliant, HighTide, Gilead, Mirum, Escient, DISC, Mitsubishi, Target RWE
Board, Committee, Journal: AASLD Hepatology Journal

David N. Assis, MD
Grant/Research Support: Gilead

Mazen Noureddin, MD, MHSc
Scientific Consultant/Advisor: Akero, Altimmune, Alligos, AstraZeneca, BI, Boston Pharma, Curve bioscience, Cytodyn, GSK, Histoindex, Kryia , Lilly, Madrigal, Merck, Novo Nordisk, OPKO, Rivus, Sagimet, Terns and Takeda
Grant/Research Support: Allergan, Altimmune, Akero, BI, BMS, Boston Pharma, Conatus, Corcept, Gilead, Galectin, Genfit, GSK, Kowa, Enanta, Madrigal, Lilly, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking and Zydus Consulting for Equity (e.g. Venture Capital Firms): Rivus Pharma, OPKO, Kryia and Akero

SPEAKERS:

Alan Bonder, MD
Scientific Consultant/Advisor: GlaxoSmithKline, Cymabay, Intercept, Theramune
Grants/Research Support: Gilead, Cymabay, Mirium, ChemomAb Ltd., Vantage Intellectual Property Rights (Patents, Royalties, Licensing Fees): Up-to-Date, Dynamed

Alina M. Allen, MD
Scientific Consultant/Advisor: Novo Nordisk, Madrigal, Boehringer Ingelheim, 89Bio, GlaxoSmithKline
Grants/Research Support: Target Pharma, Escopics, Oncoustics, Novo Nordisk, Madrigal, Boehringer Ingelheim, Siemens

Ana Sofia Garcia Moreno, MD
Nothing to Disclose

Ani Kardashian, MD
Nothing to Disclose

Aparna Goel, MD
Scientific Consultant/Advisor: Amgen, Gilead Sciences, Mirum Pharmaceuticals, Kezar Life Sciences, Intercept

Brian P. Lee, MD
Scientific Consultant/Advisor: GlaxoSmithKline, HepaTx, NovoNordisk, Ipsen, Cymabay, Altimmune
Grant/Research Support: Siemens Healthineers

Cara Mack, MD, FAASLD
Scientific Consultant/Advisor: Albireo, Ipsen  

Cynthia Levy, MD, FAASLD
Scientific Consultant/Advisor: Chemomab, Pliant, Kowa, Mirum, GSK, CymaBay, Ipsen, Intercept, Target RWE, Gilead
Grant/Research Support: Intercept, Ipsen, CymaBay, Calliditas, Kowa, Zydus, Pliant, HighTide, Gilead, Mirum, Escient, DISC, Mitsubishi, Target RWE
Board, Committee, Journal: AASLD Hepatology Journal

David N. Assis, MD
Grant/Research Support: Gilead

Elliot B. Tapper, MD, FAASLD
Scientific Consultant/Advisor: Kaleido, Takeda, Ipsen
Grant/Research Support: Ambys, Madrigal, Valeant, Novo Nordisk
Board, Committee, Journal: AGA, Liver/Biliary Nominating committee, Research Advisory

Fasiha Kanwal, MD, MSHS, AGAF, FAASLD
Grant/Research Support: Gilead, Merck

Gene Y. Im, MD, FAASLD
Scientific Consultant/Advisor: Alimentiv, Korro Boro, Echosens, Novo Nordisk

Grace L. Su, MD, FAASLD
Employee: Applied Morphonics, Prenovo

Jay Shubrook
Scientific Consultant/Advisor: Sanofi, Bayer, Madrigal, Corcept, Idorsia, Abbott, Insulet, Novo Nordisk

Jennifer Berg
Scientific Consultant/Advisor: Regeneron, Madrigal

Jessica Mellinger, MD
Scientific Consultant/Advisor: Boehringer Ingelheim, GlaxoSmithKline, Novo Nordisk

John Eaton, MD
Nothing to Disclose

Juan Pablo Arab, MD, FRCPC
Nothing to Disclose  

Maja Thiele, MD
Scientific Consultant/Advisor: Takeda, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline
Grant/Research Support: GlaxoSmithKline
Speaker’s Bureau: EchoSens, Madrigal, Novo Nordisk Intellectual Property Rights: Evido

Mark Gordon Swain, MD, MSC, FAASLD, FCAHS
Scientific Consultant/Advisor: Novo Nordisk, Gilead, Ipsen, Advanz, Abbott, GlaxoSmithKline, Mirum, Boehringer Ingelheim
Grant/Research Support: Mirum, Kowa, Gilead, Ipsen, Novo Nordisk, GlaxoSmithKline, Cymabay, Intercept, Madrigal, 89Bio, Boehringer Ingelheim, Inventiva, Galectin, Altimmune
Speakers Bureau: Gilead, Ipsen, Umecrine, Abbott

Marlyn J. Mayo, MD, FAASLD
Scientific Consultant/Advisor: Intra Sana, CymaBay, Mirum, GlaxoSmithKline, Mallinckrodt, Ipsen
Grant/Research Support: Intercept, Cymabay, Mallinckrodt, GlaxoSmithKline, Ipsen, Mirum, Target RWE

Mary E. McCarthy Rinella, MD, FAASLD:
Scientific Consultant/Advisor: Boehringer Ingelheim, Intercept, GlaxoSmithKline, Eli Lilly, Madrigal, Novo Nordisk, Cytodyn, HistoIndex, Sonic Incytes, Takeda, 89Bio, Akero, NGM Biopharmaceuticals, Sagimet

Mazen Noureddin, MD, MHSc
Scientific Consultant/Advisor: Akero, Altimmune, Alligos, AstraZeneca, BI, Boston Pharma, Curve bioscience, Cytodyn, GSK, Histoindex, Kryia , Lilly, Madrigal, Merck, Novo Nordisk, OPKO, Rivus, Sagimet, Terns and Takeda
Grant/Research Support: Allergan, Altimmune, Akero, BI, BMS, Boston Pharma, Conatus, Corcept, Gilead, Galectin, Genfit, GSK, Kowa, Enanta, Madrigal, Lilly, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking and Zydus
Consulting for Equity (e.g. Venture Capital Firms): Rivus Pharma, OPKO, Kryia and Akero

Meena B. Bansal, MD, FAASLD
Scientific Consultant/Advisor: Novo Nordisk, Madrigal, Boehringer-Ingelheim, GlaxoSmithKline, Merck, CurveBio, Boston Pharma Grant/Research Support: The Kinetix Group, NIH: RO1, Pfizer, HistoIndex, Siemens
Data Safety Monitoring Board: TREAT Consortium, Surrozen  

Michael H. Trauner, MD, FAASLD
Scientific Consultant/Advisor: AbbVie, Albireo, Agomab, Alfasigma, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk Pharma, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Janssen, Mirum, MSD, Novartis, Phenex, Pliant, Rectify, Regulus, ProQR Therapeutics Grant/Research Support: Albireo, Alnylam, Cymabay, Falk Pharma, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx Commercial Speaker's Bureau: Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk Foundation, Gilead, Ipsen, Intercept, Mirum, MSD and Madrigal Intellectual Property Rights (Patents, Royalties, Licensing Fees): co-inventor of patents on the medical use of 24-norursodeoxycholic acid (service inventions as employee) filed by the Medical University of Graz

Monika Sarkar, MD, FAASLD, MAS
Grant/Research Support: Zydus Pharmaceuticals, GlaxoSmithKline, Gilead
Principal Investigator: Zydus Pharmaceuticals

Naim Alkhouri, MD, FAASLD
Scientific Consultant/Advisor: 89Bio, Boehringer Ingelheim, Pfizer, Gilead, Echosens, Fibronostics, Novo Nordisk, Akero, Perspectum, NorthSea, Merck, Altimmune
Grant/Research Support: 89Bio, Akero, AbbVie, Altimmune, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Corcept, DSM, Galectin, Genentech, Gilead, Hepagene, Intercept, Inventiva, Ionis, Ipsen, Lilly, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Pfizer, Perspectum, Poxel, Viking, Zydus
Commercial Speaker's Bureau: Intercept, Ipsen, Mirum, Madrigal, Gilead, AbbVie, Alexion, Echosens, Perspectum

Nidhi Salan-Jakrikar
Nothing to Disclose

Pere Gines, MD, FAASLD
Scientific Consultant/Advisor: Gilead, RallyBio, Behring, SeaBeLife, Merck, Sharp and Dohme (MSD), Ocelot Bio, Roche Diagnostics International, Boehringer Ingelheim, AstraZeneca
Grant/Research Support: Gilead, Grifols
Commercial Speaker's Bureau: Pfizer

Pietro Invernizzi, MD, PhD
Nothing to Disclose

Rohit Loomba, MD, MHSc, FAASLD
Company Employee, Officer, Director: LipoNexus
Scientific Consultant/Advisor: Aardvark, Altimmune, Arrowhead, AstraZeneca, Cascade, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89bio, Takeda, Terns, Viking
Grant/Research Support: Arrowhead, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal,Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns

Rotonya M. Carr, MD, FACP, FAASLD
Scientific Consultant/Advisor: Novo Nordisk, Madrigal, Intercept
Research Grants: Merck
Expert Testimony: McCarter & English, LLP

Samuel Klein, MD
Scientific Consultant/Advisor: AbbVie, Merck, Verdiva Bio, Novo Nordisk

Scott Isaacs, MD
Nothing to Disclose

Silvia M. Vilarinho, MD, PhD
Scientific Consultant/Advisor: Albireo, Mirum, Ipsen
Grant/Research Support: Moderna Therapeutics Inc

Sonya MacParland, PhD
Nothing to Disclose

Vincenzo Ronca, MD
Scientific Consultant/Advisor: Ipsen
Grant/Research Support: Gilead

W. Ray Kim, MD, FAASLD
Scientific Consultant/Advisor: Grifols, Gilead, Novo Nordisk  

CME COMMITTEE AND STAFF REVIEWERS:

Scott Matherly, MD

Nothing to Disclose

Heather Patton, MD, FAASLD 
Nothing to Disclose

Achuthan Sourianarayanane, MD, MRCP
Grant/Research Support: Endra

Sally Cook, CMP, CHCP
Nothing to Disclose
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: April 7, 2026
Expiration Date: April 7, 2027
Powered By